A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320

Phototyping: comprehensive DNA typing for HLA‐A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence‐specific primers (PCR‐SSP)

1995 • 1,018 citations

A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalaria

1997 • 871 citations

The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL

1996 • 711 citations

Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1

1996 • 440 citations

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1991 • 334 citations

Progress in Vaccines Against Typhoid Fever

1989 • 182 citations

Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

1993 • 160 citations

Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay

1990 • 153 citations

A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)

1995 • 144 citations

Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial

1992 • 134 citations

The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1

1999 • 122 citations

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

1993 • 118 citations

Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

1994 • 110 citations

Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain

1992 • 106 citations

Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual

1991 • 104 citations

Serotyping HIV Type 1 by Antibody Binding to the V3 Loop: Relationship to Viral Genotype

1994 • 102 citations

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1994 • 96 citations

Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

1993 • 84 citations

Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group

1997 • 83 citations

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian–human immunodeficiency virus infection

1998 • 76 citations

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

1998 • 74 citations

Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59

1996 • 72 citations

Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans

1994 • 62 citations

Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals

1999 • 54 citations

Geographic Diversity of Human Immunodeficiency Virus Type 1: Serologic Reactivity to env Epitopes and Relationship to Neutralization

1992 • 50 citations

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

1996 • 47 citations

Clinical, Immunologic, and Virologic Observations Related to Human Immunodeficiency Virus (HIV) Type 1 Infection in a Volunteer in an HIV-1 Vaccine Clinical Trial

1995 • 39 citations

Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.

1998 • 39 citations

Safety and Immunogenicity of a Recombinant HIV Type 1 Glycoprotein 160 Boosted by a V3 Synthetic Peptide in HIV-Negative Volunteers

1995 • 29 citations

A Vaccinia-gp160-Based Vaccine But Not a gp160 Protein Vaccine Elicits Anti-gp160 Cytotoxic T Lymphocytes in Some HIV-1 Seronegative Vaccinees

1995 • 29 citations

Typhoid VI: A Less Reactogenic Vaccine

1992 • 23 citations

Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL

1996 • 22 citations

Immunization with Human Immunodeficiency Virus Type 1 rgp120_W61Din QS21/MPL Adjuvant Primes T Cell Proliferation and C‐C Chemokine Production to Multiple Epitopes within Variable and Conserved Domains of gp120_W61D

1999 • 17 citations

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

1997 • 16 citations

Restricted Specificity of Anti-V3 Antibodies Induced in Humans by HIV Candidate Vaccines

1997 • 10 citations

Summary of track B: clinical science.

1996 • 4 citations

Cited By (0)

No citing papers found in database